Cancer phase I clinical trials: efficient dose escalation with overdose control.

Abstract

We describe an adaptive dose escalation scheme for use in cancer phase I clinical trials. The method is fully adaptive, makes use of all the information available at the time of each dose assignment, and directly addresses the ethical need to control the probability of overdosing. It is designed to approach the maximum tolerated dose as fast as possible… (More)

Topics

  • Presentations referencing similar topics